Mammoth Biosciences is a biotechnology company that develops CRISPR-based platform for diagnostics, democratizing access to an endless variety of tests for sensing in healthcare.
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products.
Mammoth Biosciences was co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The company is headquartered in San Francisco, California.
Mammoth's revolutionary method for molecular diagnostics, enabling limitless testing possibilities. The company's CRISPR-Cas systems provide unprecedented power to edit the genome.
Mammoth is leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, to provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more.
Mammoth is addressing the current challenges of CRISPR-Cas systems and expanding the scope of use by applying our proprietary discovery platform to identify novel Cas proteins.
Mammoth is backed by Mayfield, Redmile Group, Foresite Capital, NFX, Decheng Capital, 8VC, AME Cloud, Wireframe, Senator Investment Group, and others. The company raised $150M in Series D round on Sep 09, 2021. This brings Mammoth's total funding to $219.5M to date. The new round valued the company at more than $1B post-money.